Blaine Tarr
04-18-2012, 12:25 AM
Unilife Corp (UNIS) a manufacturer and supplier of drug delivery systems is setting up for a bullish chart move. I'm watching the 4.20 and 4.25 levels very closely. As a move over this spot may bring buyers in to push the stock towards 4.60. The chart has a gap to fill to that price range after the gap down it had in November following a secondary offering of shares to the public. The stock soon bottomed thereafter, and has proved this by creating a higher low in March. Essentially meaning buyers were willing to buy it higher, a bullish sign. Therefore the resistance line of 4.25 on the chart shown below, is a barrier that if crossed could bring in more buyers who are aware of the UNIS bullish chart pattern forming.
http://content.screencast.com/users/btbulldawgs/folders/Jing/media/05bfad74-8b73-402c-af88-eded5adfb870/UNIS%204.18.png
About Unilife Corp, as stated from their latest quarterly financial statement:
We are a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems. We collaborate with pharmaceutical and biotechnology companies seeking access to innovative, differentiated devices that can enable or enhance the administration of their injectable drugs and vaccines. Secondary customers include suppliers of medical equipment to healthcare facilities and distributors to patients who self-administer prescription medication.
We have developed a broad portfolio of drug delivery systems in direct response to unmet market needs for injectable drugs including macromolecule biologics. Proprietary technology platforms include prefilled syringes with integrated safety features, auto-injectors, subcutaneous patch infusion systems, drug reconstitution delivery systems and specialized devices for targeted organ delivery.
Our lead product is the Unifill ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic alliance with Sanofi, a large global pharmaceutical company, pursuant to which Sanofi has paid us a €10.0 million exclusivity fee and has paid us €17.0 million to fund our industrialization program for the Unifill syringe. We are also in discussions with other pharmaceutical companies that are seeking to obtain access to the Unifill syringe, or other proprietary devices within our diversified portfolio.
In addition, we manufacture our Unitract 1mL insulin syringes at our FDA-registered manufacturing facility in Pennsylvania, which are designed primarily for use in healthcare facilities and by patients who self-administer prescription medication such as insulin.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8391166-82199-104356&type=sect&dcn=0001193125-12-049607
Disclosure: I have no position in UNIS at this time, but may initiate a position in the future in accordance with the suggestions I have made above. If you are interested in knowing exactly if or when I buy UNIS, you may find our live 'Trading Room' helpful. Learn more by clicking here. (http://onlinetradersforum.com/showthread.php?t=623969)
http://content.screencast.com/users/btbulldawgs/folders/Jing/media/05bfad74-8b73-402c-af88-eded5adfb870/UNIS%204.18.png
About Unilife Corp, as stated from their latest quarterly financial statement:
We are a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems. We collaborate with pharmaceutical and biotechnology companies seeking access to innovative, differentiated devices that can enable or enhance the administration of their injectable drugs and vaccines. Secondary customers include suppliers of medical equipment to healthcare facilities and distributors to patients who self-administer prescription medication.
We have developed a broad portfolio of drug delivery systems in direct response to unmet market needs for injectable drugs including macromolecule biologics. Proprietary technology platforms include prefilled syringes with integrated safety features, auto-injectors, subcutaneous patch infusion systems, drug reconstitution delivery systems and specialized devices for targeted organ delivery.
Our lead product is the Unifill ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic alliance with Sanofi, a large global pharmaceutical company, pursuant to which Sanofi has paid us a €10.0 million exclusivity fee and has paid us €17.0 million to fund our industrialization program for the Unifill syringe. We are also in discussions with other pharmaceutical companies that are seeking to obtain access to the Unifill syringe, or other proprietary devices within our diversified portfolio.
In addition, we manufacture our Unitract 1mL insulin syringes at our FDA-registered manufacturing facility in Pennsylvania, which are designed primarily for use in healthcare facilities and by patients who self-administer prescription medication such as insulin.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8391166-82199-104356&type=sect&dcn=0001193125-12-049607
Disclosure: I have no position in UNIS at this time, but may initiate a position in the future in accordance with the suggestions I have made above. If you are interested in knowing exactly if or when I buy UNIS, you may find our live 'Trading Room' helpful. Learn more by clicking here. (http://onlinetradersforum.com/showthread.php?t=623969)